VANCOUVER, Nov. 14, 2011 /CNW/ - Merus Labs International Inc. (the
"Company") announced that it has entered into a License and
Distribution Agreement with Innocoll in Canada for CollaGUARD surgical
adhesion barrier for the prevention of postoperative adhesions
following abdominal and pelvic surgery.
"Adhesions occur after most surgical procedures, and are of major
clinical, social and economic concern. The addition of CollaGUARD to
our portfolio means that thousands of patients at risk of adhesion will
have a clinically proven superior solution. We look forward to
obtaining Health Canada approval and the launch of CollaGUARD in 2012."
said Ali Moghaddam, Vice President at Merus Labs.
Dr. Michael Myers, President and CEO stated "We are pleased to announce
the expansion of our partnership with Merus to include CollaGUARD and
we look forward to the successful launch of the product in Canada."
CollaGUARD is a transparent bioresorbable film of 100% type I collagen
developed using Innocoll's proprietary CollaFilm technology. It is
approved in Europe for the prevention of postoperative adhesions in
patients undergoing abdominopelvic laparotomy or laparoscopy. When
tested in vivo, CollaGUARD increased the probability of remaining adhesion-free by
more than six fold (P < 0.001) and significantly reduced the extent and severity of adhesions
(P < 0.001).
CollaGUARD has been designed and engineered with a unique combination of
features for optimal handling, ease-of-use, and antiadhesion
performance. It is highly stable at room temperature and does not
require any advanced preparation before use. The product is non-tacky
and can be easily rolled for insertion through a trocar when implanted
laparoscopically. CollaGUARD is available in a wide variety of sizes up
to 20 x 30 cm; it may be cut and sutured if required and therefore used
efficiently across a broad range of surgeries.
About Innocoll, Inc.
Innocoll is a privately held, biopharmaceutical company focused on
biodegradable surgical implants and topically applied healthcare
products. The company develops and manufactures a range of
pharmaceutical products and medical devices using its proprietary
collagen-based technologies, CollaRx®, CollaFilm, DermaSil™, CollaPressTM and Liquicoll®. Approved products based on the Company's technologies
include: Collatamp® G, Septocoll®, CollaGUARD, Collieva®, CollaCare®,
Collexa®, Zorpreva™, and LidoColl®.
Other products in clinical and regulatory development include: CollaRx
Gentamicin Surgical Implant in phase 3 for prevention of surgical wound
infections, Cogenzia in phase 3 for the adjuvant treatment of infected
diabetic foot ulcers, and Xaracoll in phase 2b for the management of
post-operative pain. For more information, please visit www.innocollinc.com.
About Merus Labs Inc.
Merus is a specialty pharmaceutical company engaged in the acquisition
and licensing of pharmaceutical products. The Company utilizes its
expertise in the North American pharmaceutical markets and its access
to capital to acquire and license niche branded products in Canada and
United States. Merus further enhances the sale and distribution of
these products by introduction of a focused marketing and promotion
This press release may contain forward-looking statements that involve
risks and uncertainties. These statements relate to future events or
our future financial performance. In some cases, you can identify
forward-looking statements by terminology including "could", "may",
"will", "should", "expect", "plan", "anticipate", "believe",
"estimate", "predict", "potential" and the negative of these terms or
other comparable terminology. While these forward-looking statements,
and any assumptions upon which they are based, are made in good faith
and reflect our current judgment regarding the direction of our
business, actual results will almost always vary, sometimes materially,
from any estimates, predictions, projections, assumptions or other
future performance suggested in this report. Except as required by
applicable law, we do not intend to update any of the forward-looking
statements so as to conform these statements to actual results.
Investors should refer to the risks disclosed in the Company's reports
filed from time to time with securities regulatory authorities.
SOURCE Merus Labs International Inc.
For further information:
Dr. Ahmad Doroudian, Chief Executive Officer
Merus Labs International Inc.
Tel: (604) 805-7783